Key takeaways
- A July 2026 study in Joint Diseases and Related Surgery is the first controlled animal experiment to test BPC-157, TB-500 and their combination head-to-head in a tendon repair model.
- TB-500 was the only arm with a significant biomechanical result, higher maximum load to failure than vehicle, while both peptides improved histological scores of tendon organization.
- Combining the two peptides produced no additive effect on any measured outcome, which is the study’s most practically interesting finding.
- With four animals per group per outcome and a single four-week timepoint, the study is hypothesis-generating; it says nothing about human tendons.
BPC-157 and TB-500 are routinely discussed together, and often sold together, on the theory that a gastric pentadecapeptide acting on angiogenesis and nitric oxide signaling should complement an actin-binding fragment acting on cell migration. Until this summer, that theory had never been tested in a controlled experiment that included the combination as its own arm. In July 2026 a Turkish orthopedic group published exactly that experiment in the rat Achilles tendon, one of the standard models for tendon repair research.1 The result is more nuanced than the marketing around these compounds tends to be, and it is a useful case study in how to read a small preclinical paper. Wednesday supplies both peptides as research compounds, including as a blend; this note reports what the study observed in rats and where its limits lie.
The study design
Biçer and colleagues used thirty-two male rats, twelve weeks old, and performed a standardized full transection of the Achilles tendon followed by surgical repair. Animals were then assigned to four groups of eight: vehicle control, BPC-157 alone, TB-500 alone, and BPC-157 plus TB-500. Treatment was given daily by intraperitoneal injection for thirty days after surgery. At four weeks the tendons were harvested; within each group, four animals were used for biomechanical testing and four for histology.1
Three features of that design deserve emphasis before the results. First, the intraperitoneal route is systemic, not local to the tendon. Second, there was a single timepoint, so the study captures early repair, not remodeling or final tendon strength. Third, the effective sample size for any single outcome is four animals per group. The study is powered to detect large effects and nothing else.
What the histology showed
The authors scored tendon sections using two established semi-quantitative systems. The Bonar score grades cell morphology, ground substance, collagen arrangement and vascularity; the Movin score grades a similar set of features on a different scale. In both systems, a lower total indicates tissue that looks more like healthy, organized tendon.
Total Bonar scores were significantly lower than control in the TB-500 group (p = 0.016) and in the combination group (p = 0.040). Movin scores followed the same pattern, lower in TB-500 (p = 0.017) and in the combination group (p = 0.040). Picrosirius red staining under polarized light, the standard way to visualize collagen fiber maturity, showed increased type I collagen organization in the treated groups, most clearly in the TB-500 arm.1 The authors describe BPC-157 alone as improving histopathological parameters, though the abstract does not report a separate significance value for it against control on the composite scores.
What the biomechanics showed
Biomechanical testing pulls the repaired tendon to failure and records the maximum load it withstands. This is the outcome that matters most for a tendon’s function and the one least susceptible to interpretive bias. Here the result was narrower: TB-500 showed significantly higher maximum load to failure than control (p < 0.05). BPC-157 alone did not reach significance on this measure, and the combination did not outperform TB-500 alone.1
| Outcome at 4 weeks | BPC-157 | TB-500 | BPC-157 + TB-500 |
|---|---|---|---|
| Bonar score vs control | Improved; significance not separately reported | Lower, p = 0.016 | Lower, p = 0.040 |
| Movin score vs control | Improved; significance not separately reported | Lower, p = 0.017 | Lower, p = 0.040 |
| Type I collagen organization | Increased | Increased, most pronounced | Increased |
| Maximum load to failure vs control | Not significant | Higher, p < 0.05 | Not superior to TB-500 alone |
The combination finding
The most useful sentence in the paper is the last one in its abstract: combined therapy “provided no additive benefits.”1 On every outcome the combination arm resembled the TB-500 arm, and on the biomechanical outcome it did not exceed it. There are several possible readings. The two peptides may act on overlapping pathways in early tendon repair, so that one saturates the effect. TB-500’s actin-sequestering, migration-promoting activity may simply dominate at this timepoint. Or the study may be too small to distinguish “not additive” from “modestly additive.” Any of these is consistent with the data, and the authors do not claim to distinguish them.
What the finding does do is remove the assumption. The two-peptide blend, whether in a research setting or in the informal market, is premised on complementarity. This is the first controlled test of that premise in tendon, and it did not support it at four weeks in rats. That is a real result, and it is exactly the kind of result that a research supplier should report rather than bury. Wednesday’s comparison of BPC-157 and TB-500 and its note on how multi-compound studies are designed discuss why factorial designs like this one are the only way to answer the question.
A blend is a hypothesis; a four-arm experiment is the first place that hypothesis can actually fail.
How this fits the existing literature
BPC-157 has a comparatively deep preclinical tendon literature going back two decades, largely from a single Croatian group, including rat Achilles transection, transected quadriceps and medial collateral ligament models, with reported effects on tendon outgrowth, fibroblast migration and growth-hormone receptor expression in tendon cells.2 A May 2026 review in Pharmaceutics catalogued this body of work while noting that the peptide still has no validated pharmaceutical formulation, undercharacterized pharmacokinetics and human exposure data from fewer than thirty subjects in three uncontrolled pilots.3
Thymosin beta-4 and its synthetic fragment TB-500 have a thinner musculoskeletal record. A scoping review published in June 2026 mapped 80 studies on thymosin beta-4 and TB-500 and found the evidence concentrated in wound, skin, vascular and corneal applications; tendon, ligament, muscle and cartilage studies were “comparatively sparse,” and only a single study addressed TB-500 specifically rather than the full-length protein.4 The Biçer study therefore roughly doubles the direct TB-500 tendon evidence, which gives a sense of how early this field is. An August 2026 scoping review in the American Journal of Sports Medicine reached the same general conclusion across six popular peptides: 67 percent of publications were preclinical, and human data were heterogeneous and weak.5
Reading the evidence
Rat Achilles transection is a severe, standardized injury with a rapid, predictable healing course; it is not a model of chronic tendinopathy or of the partial tears common in human clinical practice. Systemic administration in a 300-gram animal does not translate to any human exposure. A four-week endpoint captures early matrix deposition, not the months-long remodeling that determines a tendon’s eventual strength. None of the outcomes in this study is a human outcome.
What the study does not tell us
It does not tell us whether either peptide affects tendon strength beyond four weeks, since there was no later timepoint. It does not tell us whether local administration would behave differently from intraperitoneal. It does not establish a mechanism; the histology is descriptive and there was no molecular readout of angiogenesis, nitric oxide signaling or actin dynamics that would connect the observed collagen organization to the proposed pathways. It does not report on adverse findings, and it does not include a dose-response component, so it cannot say whether more or less of either compound would have changed the picture. And, at four animals per outcome per group, a single unusual specimen could shift a mean.
These are not criticisms so much as a description of what a pilot study is. The paper’s contribution is to have run the four-arm comparison at all, and to have reported a null combination result plainly.
Why researchers will care
For groups working in tendon biology, the study offers a template, Achilles transection, thirty days, Bonar and Movin scoring, load to failure, against which further factorial studies with larger groups and later timepoints can be run. It also reframes the question. Rather than “does the combination work better,” the next experiments should ask why TB-500 carried the biomechanical signal, whether that reflects its known effect on cell migration into the repair site, and whether BPC-157’s histological effect would emerge as a strength effect at a later timepoint. Both compounds are supplied by Wednesday for research use only, with batch-specific certificates in the COA library; for background on each, see the BPC-157 research overview and the TB-500 and thymosin beta-4 note.
Frequently asked questions
Does BPC-157 heal tendons?
In rat models, including the July 2026 Achilles transection study, BPC-157 has been associated with improved histological organization of healing tendon. There are no controlled human trials of BPC-157 in tendon injury, so the question has no answer for people. Research-grade BPC-157 is not an approved drug.
Is TB-500 better than BPC-157 for tendon research?
In the one head-to-head rat study published so far, TB-500 was the only arm with a significant increase in maximum load to failure, and it also had the stronger histological effect. That is one four-week experiment with four animals per outcome group, so it should be read as a signal to investigate, not a ranking.
Is combining BPC-157 and TB-500 more effective?
Not in this study. The combination arm matched TB-500 alone on histology and did not exceed it on biomechanics; the authors concluded there were no additive benefits at four weeks. This is the first controlled test of the combination in tendon, and it did not support the complementarity hypothesis.
What is the Bonar score?
The Bonar score is a semi-quantitative histological grading system for tendon that rates cell shape, ground substance, collagen arrangement and vascularity. Lower totals indicate tissue closer to normal, organized tendon. The Movin score is a related system used in the same paper.
Where was the study published?
In Joint Diseases and Related Surgery, volume 37, issue 3, pages 822–837, published July 23, 2026, with the DOI 10.52312/jdrs.2026.2951 and PubMed ID 42542926.
References & further reading
- Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Yaprak Bayrak B. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837. doi:10.52312/jdrs.2026.2951 / PMID 42542926
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. doi:10.1016/s0736-0266(03)00110-4
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625
- McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Appl Sci. 2026;16(12):6202. doi:10.3390/app16126202
- Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. doi:10.1177/03635465261464420 / PMID 42578445